

## Best Micro-Cap Stock Pick for July–Dec 2025

**Objective:** With **\$32.13** remaining capital, identify **one U.S.-listed micro-cap** (market cap < \$300M) trading under ~\$1.50/share that offers the highest **5.5-month upside (July 8 – Dec 27, 2025)**. We compare **Muscle Maker Inc. (GRIL)** – now *Sadot Group Inc.* – against several other high-upside micro-caps, evaluating catalysts, risks, and trade specifics (position size and stop-loss). Ultimately, we recommend the single best pick to **maximize portfolio value by end of 2025**.

### GRIL (Muscle Maker Inc. / Sadot Group Inc.) – \$1.39; Food & Agri Supply Chain <sup>1</sup> <sup>2</sup>

- **Catalyst & Thesis:** *Sadot Group* (formerly Muscle Maker “GRIL”) pivoted from restaurants to **global agri-food trading** in late 2022 <sup>3</sup>. This transformation drove explosive revenue growth – over **\$500 million total revenue** in the first 8 months under new management <sup>4</sup>, with Sadot sustaining **>\$45M in monthly sales** for eight consecutive months <sup>5</sup>. The thesis is that the market has *undervalued* this tiny ~\$45M-cap company (shares ~\$1.39 <sup>6</sup>) relative to its revenue scale <sup>4</sup>. If Sadot can translate its booming commodity trading and African farming ops into **net profit**, or if it secures a major partnership/asset sale, the stock could **re-rate** sharply higher from current levels.
- **Upside Catalyst:** No single scheduled event, but upcoming **earnings reports** (Q2–Q3 2025) may reveal **positive net income** from Sadot’s operations. Any quarter of solid profits or a strategic deal could ignite a revaluation rally. Additionally, Sadot’s *Pokemoto* franchise restaurant arm continues expanding (50 franchises signed <sup>7</sup> <sup>8</sup>), which, though small, adds growth on the food-service side.
- **Red Flags: Dilution risk** is significant. GRIL’s partnership with UAE-based **AGGIA** is *performance-based*: AGGIA **earns GRIL shares by generating net income** for Sadot <sup>9</sup> <sup>7</sup>. In fact, AGGIA can earn up to **~14.42 million shares** (nearly half the current share count) by delivering \$22.54M cumulative net income at a *fixed \$1.5625/share* formula <sup>7</sup> <sup>10</sup>. This arrangement aligns incentives but will **dilute existing shareholders** as Sadot becomes profitable <sup>11</sup> <sup>12</sup>. The *flip side*: if AGGIA hits those profit targets, GRIL’s fundamentals improve dramatically – but the stock’s upside could be tempered by the expanded share count. Another concern is GRIL’s **Nasdaq compliance**; shares traded as low as \$0.30 in the past year <sup>13</sup>, and a sustained drop back below \$1 could risk delisting (the stock already underwent a **name/ticker change** to Sadot **SDOT** in 2023 <sup>3</sup> <sup>14</sup>, though no reverse split yet). Liquidity is moderate (~365K avg volume <sup>15</sup>), but any sharp decline or market turmoil could make exiting difficult. Lastly, commodity trading is low-margin and cyclical; execution missteps (e.g. a bad trading bet or crop issue) could hurt Sadot’s earnings.
- **Trade & Stop-Loss: Position:** ~\$32 buys ~23 shares of GRIL/SDOT. Given volatility, a **stop-loss ~\ \$1.00** is advised (~–28%). This cuts risk if GRIL reverses its uptrend. \$1.00 is a psychological and technical support (also the Nasdaq minimum bid threshold); a break below would signal weakening momentum and increase delisting risk.

**Verdict:** *Sadot (GRIL)* offers a compelling deep-value story (9x revenue run-rate!). However, the absence of a hard **near-term catalyst** and the overhang of dilution make it **high-risk**. Unless clear signs of profitability emerge by Q3, stronger catalyst-driven micro-caps below may present better *risk/reward* for a 5.5-month horizon.

## MULN (Mullen Automotive) – \$0.21; EV Manufacturer <sup>16</sup>

- **Catalyst & Thesis:** *Mullen* is a heavily beaten-down EV startup that could see a speculative resurgence. The company is relaunching its flagship **FIVE RS electric crossover** with a planned **December 2025 sales launch in Germany** <sup>17</sup>. The FIVE RS boasts eye-popping specs (1100+ hp, 0–60 in <2s, 800V architecture) aimed at the high-performance EV niche <sup>18</sup> <sup>19</sup>. If Mullen successfully **completes on-road testing and homologation** in Europe and meets its year-end launch timeline <sup>17</sup> <sup>20</sup>, it would mark the company's first real revenue from consumer EV sales – a *massive milestone* that could ignite the stock. Bulls also note Mullen's recent integration of **Bollinger Motors** (commercial EVs) and its acquisition of battery tech assets, which led to a 143x YOY revenue jump (\$5M in Q2 2025 vs. \$33K prior year) as initial vehicle orders were booked <sup>21</sup>. Any **big order news or a short-squeeze** (MULN is a popular retail/meme stock) could send shares sharply higher from mere pennies.
- **Upside Catalyst:** The **Germany launch (Dec 2025)** is a clear focal point <sup>17</sup>. Leading up to that, we may see catalysts such as **EU homologation approval**, first international **pre-orders or partnerships**, and progress on U.S. homologation. Notably, Mullen just settled a major lawsuit and increased its Bollinger stake to 95%, eliminating significant debt <sup>22</sup> <sup>23</sup> – improving its balance sheet. Additionally, in June Mullen announced a **\$1.4M purchase order** for its Class 3 trucks and a legal settlement that *removed toxic financing (GEM)*, which temporarily boosted sentiment <sup>24</sup> <sup>25</sup>. Any **positive news barrage** into year-end (e.g. a **U.S. government fleet deal** or meeting its production milestones) could trigger a speculative frenzy given MULN's *low absolute price*.
- **Red Flags:** Mullen is **extremely high-risk**. The company has diluted shareholders relentlessly to fund operations – executing a **1-for-100 reverse stock split on June 2, 2025** just to regain Nasdaq compliance <sup>16</sup> <sup>26</sup>. That split slashed the float from ~80M to ~0.8M shares <sup>26</sup> – yet within weeks, heavy new issuance ballooned the share count again (daily volumes of 30–300+ million *post-split* shares in July suggest substantial dilution). Indeed, Mullen's market cap sits under ~\$3M <sup>27</sup>, implying severe financial distress. The **stock has plummeted >99%** over the past year through successive dilutions and may face another **Nasdaq delisting** if it can't stay above \$1.00 (post-split it already collapsed back to ~\$0.21 <sup>28</sup>). *Cash burn* is a major concern – Mullen spent ~\$67M in Q1–Q2 2025 on operations <sup>21</sup> and likely must raise more capital, meaning *further dilution is almost certain*. Additionally, execution risk is huge: launching a supercar-EV in Europe by year-end is an aggressive timeline; any delay or failure would crush what little market confidence remains. Finally, insider credibility is low – CEO David Michery has overpromised in the past, and Bollinger (subsidiary) is entangled in legal disputes <sup>29</sup>. In short, MULN is a **“lottery ticket”**: it could multiple-fold on a surprise success or literally go to zero (bankruptcy or delisting) if plans falter.
- **Trade & Stop-Loss: Position:** ~\$32 buys ~150 shares of MULN. Given the *binary outcome* nature, a loose stop is needed to avoid whipsaw. We suggest a **stop-loss ≈ \$0.10** (about –50%) – below the all-time lows. If MULN breaks \$0.10, it likely means bankruptcy fears or a death spiral of dilution, at

which point it's prudent to cut losses. This wide stop tolerates volatility while limiting worst-case loss. Only risk money you can afford to lose – MULN is highly speculative.

**Verdict:** Mullen offers *maximum* upside (a successful FIVE RS launch could 5–10× the stock from sub-\$0.25). However, the odds of execution are low and ongoing dilution is eroding value. This is an **ultra-speculative play** suitable only if you seek a potential home run and can tolerate a total loss. We prefer a pick with a more *balanced* risk/reward profile and a clearer catalyst path.

## AZTR (Azitra Inc.) – \$0.25; Biotech (Dermatology) <sup>30</sup> <sup>31</sup>

- **Catalyst & Thesis:** *Azitra* is a micro-cap **biotech** (market cap ~\$3.6M <sup>31</sup>) developing **microbiome-based therapies for rare skin diseases**. Its lead candidate **AZT-01** is a topical live biotherapeutic for a devastating genetic skin disorder (recessive dystrophic epidermolysis bullosa, RDEB). **Crucial catalyst: Phase 2/3 trial data for AZT-01 are expected in Q4 2025** <sup>32</sup>. Positive Phase 3 results could be transformative – AZT-01 would be the *first-ever* microbiome therapy to treat a genetic skin disease <sup>33</sup>, likely attracting partnership or acquisition interest. Given Azitra's tiny valuation, a successful trial could send shares skyrocketing (multi-bagger potential). The company is also advancing a second program (AZT-02 for Netherton syndrome) with an IND filed mid-2025 <sup>32</sup>, adding pipeline value. The **thesis:** Azitra's platform (engineered beneficial bacteria for skin) is cutting-edge; if it validates in Phase 3, the upside is enormous relative to its micro-cap size.
- **Upside Catalyst: Phase 2/3 top-line readout (late 2025)** – this is the high-conviction event. The **Pharmasalmanac** specifically highlights Azitra as one of “five biotechs” nearing critical 2025 milestones, noting **Phase III EB (RDEB) results due Q4 2025** <sup>32</sup>. Success would not only make FDA approval in 2026 likely, but also position Azitra as a *buyout target* (big pharma frequently acquires tiny biotechs after positive pivotal trials in rare diseases). Additionally, **regulatory designations** (e.g. Fast Track, Orphan) could drop before year-end, boosting the stock. Even before data, speculation alone might build as we enter Q4, given the low float. Any *early hints* (like an interim analysis or trial completion announcement) could spike shares.
- **Red Flags: Financing risk is critical.** Azitra is extremely under-capitalized – it raised only ~\$2.4M in early 2025 via offerings <sup>34</sup> <sup>35</sup>. While it secured a *\$20M equity facility* in April 2025 <sup>36</sup>, tapping that will dilute shareholders (potentially by **hundreds of percent** given the low price). In fact, Azitra's NYSE-American listing itself is at risk if shares stay at ~\$0.25; sub-\$1 stocks can face compliance issues (though NYSE American rules are more lenient than Nasdaq's). The stock could also **reverse split** if needed to maintain listing. Furthermore, **clinical risk** is very high: RDEB is a challenging disease, and while interim data showed some wound healing benefit (60% vs 15% placebo) <sup>32</sup>, there's no guarantee final results will meet endpoints. A trial *failure* would likely crash the stock (down to cash value, potentially pennies). Liquidity is low (stock often trades <\$100K daily), so it may be hard to exit on bad news. Another concern: Azitra's **cash runway** – if Phase 3 readout slips into late December, the company might need to raise money *before* data to keep operating, which could hammer the stock price. Insiders hold significant shares (post-IPO in 2023), but recent offerings indicate dilution is ongoing at these low prices, which could continue to overhang the stock.
- **Trade & Stop-Loss: Position:** ~\$32 can buy **128 shares** at \$0.25. This is a *binary biotech bet*, so use a **hard stop-loss ~\$0.15** (–40%) to guard against a downward spiral (e.g. if financing troubles mount or trial news leaks negatively). \$0.15 was near all-time lows; a break below that would signal extreme

distress. Alternately, one might **size this small** and accept the risk of a total loss without a tight stop (to avoid being whipsawed by volatility). Given the tiny position cost, some investors may treat it as an “all or nothing” catalyst play. If opting for a stop, keep it wide due to low liquidity.

**Verdict:** Azitra offers **explosive upside** if Phase 3 is a hit – potentially the highest % gain of all candidates here. However, it’s essentially a **biotech moonshot** with substantial chances of failure or dilution before the catalyst. It’s suitable only if you seek a high-risk biotech gamble. More prudent is to pair such a bet with a tighter thesis/catalyst... which leads us to stronger contenders below.

## INBS (Intelligent Bio Solutions) – \$1.70; MedTech (Drug Screening)

37

- **Catalyst & Thesis:** *Intelligent Bio Solutions* is a ~\$12M market cap company pioneering **non-invasive drug testing**. Its flagship product, the **Intelligent Fingerprinting Drug Screening System**, uses a fingerprint sweat sample to detect drugs within 10 minutes – a novel, convenient solution for workplace drug testing. **Catalyst:** INBS is on track to receive **FDA 510(k) clearance in 2025** for U.S. launch <sup>38</sup> <sup>39</sup>. The company has already achieved *commercial traction overseas* – over **1,000 fingerprint reader devices installed** as of mid-2024 (with >65% YoY growth) <sup>40</sup> <sup>41</sup>, and rising recurring sales of test cartridges. The **thesis:** As INBS brings this proven product to the U.S. (the largest drug-testing market), it could rapidly scale revenue. A successful FDA clearance by Q4 2025 would open the floodgates for U.S. sales and partnerships, potentially making INBS a lucrative acquisition target (e.g. by a larger diagnostics firm) given its unique tech. Notably, the *FDA has already classified INBS’s cartridges as a Class II device requiring 510(k)* – the regulatory pathway is defined and presumably well underway <sup>39</sup>. With the stock around \$1.70 (down ~6% over the past year <sup>37</sup>), sentiment is modest – leaving room for significant upside on positive developments.

- **Upside Catalyst:** The key catalyst is **FDA clearance news**, which could drop anytime in 2H 2025. Management has indicated the U.S. launch remains “on track for 2025” <sup>38</sup> – suggesting a 510(k) decision possibly by Q4. **Approval would be game-changing:** it enables INBS to start selling in the U.S., likely accompanied by announcements of **distribution deals** or pilot programs with U.S. employers. Even before formal clearance, INBS is expanding globally – recent press releases highlight **rapid adoption in Europe and APAC** (e.g. a major Australian company deploying INBS’s system across 20+ sites) <sup>42</sup> <sup>43</sup>. These deals build revenue and validate the product’s demand. Additionally, INBS securing any **large U.S. pilot contract** (for example, a government agency or big corporation trialing the fingerprint test) could spike the stock in anticipation of broader rollout. The company’s **milestone achievements** (1000+ devices, 20% YoY consumables growth <sup>44</sup> <sup>45</sup>) show it’s progressing even pre-FDA – continued strong operational news could gradually lift the share price. Finally, INBS has a relatively low float and ~10% short interest <sup>46</sup> <sup>47</sup>; a series of good news could fuel a *short squeeze* amplifying gains.

- **Red Flags: Regulatory risk:** While 510(k) clearance is expected, delays or an FDA request for more data could push the timeline out (the FDA occasionally slows down novel drug-test devices). Any hint of delay could hurt the stock. **Cash & dilution:** INBS had only about \$9M enterprise value as of July <sup>48</sup>, implying limited cash on hand. It likely will need to raise capital to fund the U.S. launch and manufacturing scale-up. Indeed, INBS expanded its ATM (at-the-market offering) program in April, **tripling its capacity to \$7.1M (with ~33% potential dilution)** <sup>49</sup> <sup>50</sup>. Issuing those shares could

weigh on the stock (though ideally they'd do it after a price pop on FDA news). Also, insiders own a large chunk, but any insider selling or further equity financing would be a negative signal. **Market adoption risk:** The fingerprint test is innovative, but U.S. customers may be slow to change from traditional urine tests. If clearance comes late in 2025, meaningful U.S. revenue might not ramp until 2026, so traders could lose patience. Additionally, INBS's low market cap means it's at risk of volatility or even a reverse split if shares drop – it briefly dipped under \$1 in early 2025 <sup>51</sup>. However, at \$1.70 it's compliant with Nasdaq. Liquidity (avg volume ~500K/day) is decent but not huge; any *bad news* could cause an outsized drop. Overall, though, INBS's risks are more about execution and funding – less existential than many micro-caps (the product *works* and sells overseas, de-risking it somewhat).

- **Trade & Stop-Loss: Position:** ~\$32 buys ~18 shares at \$1.70. We recommend a **stop-loss around \ \$1.00** ( $\approx -40\%$ ), just below the key \$1 level. This guards against a scenario of FDA setbacks or heavy dilution pulling the stock under \$1 (which would also raise Nasdaq compliance issues). A tighter stop (e.g. \$1.20) could also be used if you prefer ~30% max risk, but note that micro-cap swings could prematurely trigger it. At ~\$1.00, you exit only if the stock decisively breaks support and sentiment likely turned bearish (e.g. no clearance by mid-Dec). As INBS has tangible revenue, one could also hold through moderate dips if the FDA decision is still pending – but discipline is important if the story deteriorates.

**Verdict:** INBS offers an attractive **catalyst-driven play** with comparatively moderate risk. The fingerprint drug-test technology is gaining real traction abroad and an imminent FDA clearance could unlock substantial value. While not as explosive as a biotech trial, the probability of success is higher (510(k) devices have a good approval rate). **For a balanced approach – meaningful upside on a clear event, with less chance of total loss – INBS is a strong contender.**

## IINN (Inspira Technologies) – \$1.54; Medical Devices (Respiratory) <sup>52</sup>

- **Catalyst & Thesis:** *Inspira Technologies* is a ~\$25M market cap Israeli med-tech company addressing advanced respiratory care (ECMO and beyond). **Major Catalyst: Inspira just secured a transformative \$22.5 million purchase order for its FDA-cleared ART100 blood oxygenation system** <sup>53</sup> <sup>54</sup> – **an enormous revenue influx relative to its size. This binding order (from an overseas company with government ties) will be fully paid in 2025** <sup>54</sup>, marking Inspira's transition from R&D to full-scale commercialization. **The ART100 is already FDA-cleared for use in cardiopulmonary bypass (and ECMO internationally)** <sup>55</sup>, and this order validates real-market demand. The thesis: **With this sale (and cash coming in), Inspira can fund growth without heavy dilution and demonstrate its tech's value, possibly leading to follow-on orders and government adoption. Indeed, management noted this \$22.5M is just a "small portion" of the addressable market and that they're in advanced talks with additional healthcare and government entities for further deployments** <sup>56</sup> <sup>57</sup>. This suggests a pipeline of deals – each could be a catalyst. Inspira's product addresses a critical need (oxygenating blood for patients in respiratory failure) and could disrupt traditional ECMO with a simpler, cost-effective solution. **Given one big customer is on board, the upside scenario\*\* is rapid revenue ramp and perhaps strategic interest from larger med-tech firms.**

- **Upside Catalysts: 1) Revenue & Earnings Surprise:** Inspira will likely report **blowout revenues** in coming quarters as the \$22.5M order is delivered (full payment by end of 2025 <sup>54</sup>). For context, the company's prior annual revenue was near zero – so this is a *step-change*. As milestones are met

(onboarding, manufacturing, deployment), press releases could flow. **2) Additional Contracts:** Management explicitly said they're negotiating with more healthcare companies and governments across multiple regions, with agreements expected "in the near term" <sup>57</sup>. Any announcement of a **second large order** (or a national healthcare partnership) could send IINN soaring further. In fact, *high-level talks* with a certain national government were scheduled for July 8, 2025 to plan a strategic collaboration <sup>58</sup> – a positive indicator that Inspira may secure **public health system deals**. **3) Short Squeeze/Momentum:** The stock jumped +30% on July 7 to \$1.54 <sup>52</sup> after this news, and now has strong momentum, plus new analyst coverage ("Buy" with \$2+ target) <sup>59</sup>. With a relatively low float and increasing volume, IINN could attract momentum traders; any positive follow-up news might trigger a squeeze. **4) 2025 Product Milestones:** Beyond ART100, Inspira is developing the **ART500** (an awake ECMO-like system). Any update on FDA trials or progress there could add speculative value, though main focus is on commercial execution of ART100 now. Importantly, unlike many micro-caps, Inspira already has an FDA-cleared device – *regulatory risk is low*. The catalysts here are *commercial* – which the recent order shows are trending favorably.

- **Red Flags: Dilution & Funding:** Inspira had been cash-limited pre-order. It filed a shelf and expanded its ATM program in April 2025, **tripling its ATM capacity to \$7.1M** (which implied ~33% dilution if fully used) <sup>49</sup>. The *good news*: the \$22.5M incoming cash reduces the immediate need for financing. The *caution*: the company **may still issue some shares** to fund expansion (indeed, it opportunistically raised ~\$1.9M via a share/warrant offering in April at ~\$2.00 <sup>60</sup> <sup>61</sup>). Investors should watch if insiders or the company sell into the post-news rally – that could cap the stock. **Customer Concentration:** This huge order is from one private company outside the U.S. <sup>53</sup> <sup>54</sup>. Relying on a single buyer poses risk; any issue with that deployment could hurt revenues. It also means most 2025 revenue eggs are in one basket (though new deals may diversify this). **Execution Risk:** Fulfilling a \$22.5M order is a big operational challenge for a small firm – production delays or quality issues could jeopardize customer relationships. Also, expanding globally (government deals) requires navigating regulatory and logistical hurdles in each country (though ART100 is cleared in U.S. and CE Mark would be next). **Share Volatility:** IINN has been volatile; it traded ~\$0.60–0.90 for months then spiked to \$1.50+ on news. Any lack of follow-through (if, say, further orders don't materialize for a while) could see the stock pull back once the initial euphoria fades. Additionally, though one analyst is bullish, this is a micro-cap – investor awareness is limited, and broader market selloffs can hit it hard. Finally, **competition** in ECMO/oxygenation: big players like Getinge or Medtronic offer ECMO devices. Inspira must prove its tech is superior or more cost-effective to win long-term. So far, the large order is a strong vote of confidence, but competition is an underlying risk.

- **Trade & Stop-Loss: Position:** ~\$32.13 can purchase **20 shares of IINN** at ~\$1.50. IINN has positive momentum, but to protect gains and principal, use a **stop-loss around \$1.10** (about –25% from \$1.50). This is just below the ~\$1.18 level that acted as a breakout point before the recent surge <sup>52</sup>. If the stock retraces and falls under ~\$1.10 without quick recovery, it may signal the rally is over or news didn't meet expectations. Another strategy is a **trailing stop ~20%** to ride the uptrend as long as it lasts. Given the strong news flow expected (multiple deals possible), one might give IINN a bit of room; however, a drop back into the \$1.0x range would warrant caution. With the stock's newfound liquidity (tens of millions of shares traded post-news), stop orders are more likely to execute at intended levels (slippage risk is lower than in thinly traded names).

**Verdict:** *Inspira (IINN)* appears to offer the best blend of substantial upside and achievable catalysts. The company has high-conviction events unfolding now – a massive revenue order (guaranteed to hit by year-end) and the prospect of additional contracts or partnerships in the coming months <sup>57</sup>. Unlike many micro-caps, this is not just speculative science; it's a revenue-generating product with real market uptake. There are risks, but Inspira's cash infusion and growing pipeline of deals mitigate many typical micro-cap concerns. The stock has already reacted to news, yet still trades around \$1.5 (below analysts' ~\$2 targets <sup>59</sup>) with room to run as the story develops. Given our goal of maximizing returns by Dec 2025, IINN offers an attractive risk/reward profile – a funded company executing on sales into a large market, with potential for further positive surprises.\*\*

## Recommendation: Buy IINN (Inspira Technologies) – Top Pick for H2 2025

After careful comparison, **Inspira Technologies (IINN)** emerges as the **single best micro-cap candidate** to deploy the \$32.13. Here's why:

- **High-Conviction Catalyst:** IINN is in the midst of a *commercial breakthrough*. The **\$22.5M order** (to be fully paid in 2025 <sup>54</sup>) and ongoing government/enterprise negotiations provide **confidence in a strong news flow** through year-end. This isn't a binary "maybe" catalyst – it's a real revenue event currently unfolding, with likely follow-ups.
- **Maximum Return Potential:** From \$1.50, IINN could plausibly double or more by Dec 2025. If additional contracts (e.g. a **national healthcare deal**) are signed, the stock's upside could be very significant (e.g. *small-cap medtech peers often trade at 3–5× sales; IINN's \$22.5M order alone is ~0.9× its current cap*). Unlike GRIL (whose value is tied up in low-margin trading) or MULN/AZTR (which are nearer all-or-nothing bets), IINN offers a scenario where **multiple positive outcomes** (revenue ramp, new deals, profitable quarters) can drive sustained gains. It's telling that management expects this *one order* to herald a "broad activation" of its model with "next wave of global deployments already underway" <sup>62</sup>.
- **Risk Management:** IINN's risks – dilution and execution – are **relatively manageable** now. The huge contract revenue should reduce dilution needs (unlike GRIL or MULN, which *will* dilute to survive). The product already has FDA clearance, lowering regulatory uncertainty (contrast with INBS or AZTR which still await approvals/data). We have set a stop-loss (~\$1.10) to cap downside around 25–30%. In comparison, other picks carry higher risk of catastrophic loss: e.g. GRIL could flounder with no catalyst, MULN could fail to deliver and get delisted, AZTR could tank on trial failure. INBS is another solid choice, but its main catalyst (FDA clearance) is likely a one-time pop; IINN enjoys a **series of catalysts** (order fulfillment, earnings surprise, subsequent deals) that can compound.

**Trade Plan:** Buy **20 shares of IINN** at market (~\$1.50, total ~\$30). This leaves a small cash buffer for flexibility. Set a **stop-loss at \$1.10** to protect capital <sup>52</sup>. Monitor upcoming news: IINN's Q3 earnings (due Nov) should reflect initial order revenue – a **profit could be a game-changer** for perception. Also watch for press releases on new agreements (the company tends to announce material events promptly). If shares rise markedly before December, consider raising the stop to lock in profits. By late December 2025, we anticipate IINN's price to be significantly higher on the back of its commercial momentum (with Wall Street possibly starting to recognize the turnaround).

**Bottom Line: Buy IINN** for its rare combination of *imminent tangible catalysts* and *transformational upside*. This micro-cap has moved from promise to execution at just the right time to potentially **maximize our portfolio's year-end return**. All things considered – if one micro-cap stock is to make the most of \$32.13 in 5½ months – **Inspira Technologies is the top pick**.

11 54

---

1 6 13 15 Muscle Maker (GRIL) Stock Price, News & Analysis

<https://www.marketbeat.com/stocks/NASDAQ/GRIL/>

2 3 4 5 14 Muscle Maker Inc. (纳斯达克股票代码：GRIL) 宣布更名并更名为Sadot Group Inc. (纳斯达克股票代码：SDOT)

<https://www.moomoo.com/hans/news/post/25377644/muscle-maker-inc-nasdaq-gril-announces-name-change-and-rebranding>

7 8 9 10 11 12 Muscle Maker Inc's New Subsidiary, Sadot LLC, Posts \$54.19 Million Revenue in First 30 Days of Operation | GRIL Stock News

<https://www.stocktitan.net/news/GRIL/muscle-maker-inc-s-new-subsiidiary-sadot-llc-posts-54-19-million-nxchr86n8b17.html>

16 21 26 29 Mullen Automotive confirms reverse stock split | Clean Trucking

<https://www.cleantucking.com/battery-electric/article/15747232/mullen-automotive-confirms-reverse-stock-split>

17 18 19 20 Mullen Announces FIVE RS Launch and Vehicle Sales in Germany in December 2025

<https://news.mullenusa.com/mullen-announces-five-rs-launch-and-vehicle-sales-in-germany-in-december-2025>

22 Newsroom | Mullen | Press Release - Mullen Automotive

<https://news.mullenusa.com/>

23 MULN - Mullen Automotive Inc Latest Stock News & Market Updates

<https://www.stocktitan.net/news/MULN/>

24 25 Mullen News: Reverse Split, GEM Settlement & \$1.4 Million Order

<https://www.autoconnectedcar.com/2025/05/mullen-news-reverse-split-gem-settlement-1-4-million-order/>

27 Mullen Automotive, Inc. (MULN) Stock Price, News, Quote & History

<https://finance.yahoo.com/quote/MULN/>

28 Mullen Automotive, Inc. (MULN) Stock Historical Prices & Data

<https://finance.yahoo.com/quote/MULN/history/>

30 Stock Quote & Chart - Investor Relations | Azitra, Inc.

<https://ir.azitracinc.com/stock-information/stock-quote-chart>

31 AZTR - Azitra, Inc. (NYSEAM) - Share Price and News

<https://fintel.io/s/us/aztr>

32 33 Five Biotechs Approaching Critical Milestones in 2025

<https://www.pharmasalmanc.com/articles/five-biotechs-approaching-critical-milestones-in-2025>

34 35 36 Azitra (AZTR) Stock Price & Overview

<https://stockanalysis.com/stocks/aztr/>

37 47 48 INBS - Intelligent Bio Solutions Inc. (NasdaqCM) - Share Price and News

<https://fintel.io/s/us/inbs>



38 INBS' FDA Clearance Process Remains on Track for U.S. Launch

<https://ibs.inc/2025/03/25/inbs-fda-clearance-process-remains-on-track-for-2025-us-launch/>

39 40 41 42 43 44 45 Intelligent Bio Solutions Inc. Achieves Major Milestone

<https://www.globenewswire.com/news-release/2024/08/21/2933492/0/en/Intelligent-Bio-Solutions-Inc-Achieves-Major-Milestone-with-Over-1-000-Installed-Intelligent-Fingerprinting-Drug-Screening-Readers-as-of-June-30-2024.html>

46 Price Prediction for 2025. Should I Buy INBS? - Stock - Intellectia AI

<https://intellectia.ai/stock/INBS/forecast>

49 50 [424B5] Inspira Technologies Oxy B.H.N. Ltd. Warrant Prospectus ...

<https://www.stocktitan.net/sec-filings/IINN/424b5-inspira-technologies-oxy-b-h-n-ltd-warrant-prospectus-supplemen-30ddf42a0178.html>

51 What is Intelligent Bio (USA Stocks:INBS) Market Value 2025?

<https://www.macroaxis.com/market-value/INBS>

52 Inspira Technologies Oxy Bhn Ltd. Stock Forecast - StockInvest.us

<https://stockinvest.us/stock/IINN>

53 54 55 56 57 62 Inspira Technologies Secures \$22.5 Million Purchase Order for ART100 System, Signaling Major Commercial Milestone | Nasdaq

<https://www.nasdaq.com/articles/inspira-technologies-secures-225-million-purchase-order-art100-system-signaling-major>

58 Inspira in High-Level Government Talks to Advance National ...

<https://finance.yahoo.com/news/inspira-high-level-government-talks-125000595.html>

59 Litchfield Hills Initiates Coverage of Inspira Technologies Oxy B.H.N. ...

<https://www.nasdaq.com/articles/litchfield-hills-initiates-coverage-inspira-technologies-oxy-bhn-iinn-buy-recommendation>

60 Inspira Technologies Expands Share Offering Capacity in April 2025

<https://www.tipranks.com/news/company-announcements/inspira-technologies-expands-share-offering-capacity-in-april-2025>

61 Inspira Technologies Expands Share Offering Capacity in April 2025

<https://www-web.itiger.com/news/2526032544>